Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting

Key Terms

cell-free DNA medical

Fragments of DNA that float freely in the bloodstream after being released by dying or damaged cells, like puzzle pieces carried downstream that hint at what’s happening upstream. Investors care because measuring these fragments enables non‑invasive tests — for example to detect cancer, monitor treatment response, check pregnancy health, or spot organ rejection — so advances, approvals, or reimbursement changes can quickly affect companies that develop the tests and related technologies.

precision medicine medical

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

LinkedSNP technical

A linked SNP is a specific single-letter change in DNA that is inherited together with another genetic variant because they sit close to each other on the chromosome. For investors, linked SNPs matter because they can serve as reliable markers for disease risk, drug response, or patient subgroups when a directly causal mutation is hard to measure — like using a nearby street sign to find a hidden house — and that can affect the value of diagnostics, therapies, and regulatory decisions.

non-invasive prenatal screening medical

A blood test performed during pregnancy that looks for fragments of the unborn baby’s genetic material to screen for chromosomal conditions without needing surgical procedures or needles into the uterus. It matters to investors because uptake, accuracy, regulation, and insurance coverage drive demand and revenue for labs, diagnostic companies and device makers; think of it as a low-risk early warning system whose adoption can reshape a market.

NIPT medical

Non-invasive prenatal testing (NIPT) is a blood test that screens for certain genetic conditions in a fetus by examining small fragments of the baby’s DNA present in the pregnant person’s blood, avoiding invasive procedures that enter the womb. It matters to investors because test uptake, accuracy, regulatory approval, and pricing determine revenue and margins for companies offering the technology—think of NIPT as a safer, earlier health check (like a smoke alarm for genetic risk) that can drive demand and competitive dynamics in healthcare markets.

SNP-based technical

SNP-based means something (a test, analysis, therapy or product) that relies on single nucleotide polymorphisms — the tiny single-letter differences in DNA that can influence traits or disease risk. Think of SNPs as single-letter typos in a long instruction manual; SNP-based approaches read those letters to classify risk, guide drug choices, or target populations. For investors, SNP-based tools matter because they can drive market opportunity, regulatory review, and reimbursement decisions in personalized medicine.

cfDNA medical

Cell-free DNA (cfDNA) is short fragments of genetic material that float freely in the bloodstream after cells die and release their contents. Investors care because cfDNA can be sampled with a simple blood draw to reveal signs of pregnancy complications, organ damage, or cancer without invasive procedures, making it the basis for high-growth diagnostic tests, monitoring tools and companion products that can change how diseases are detected and treated.

vanishing twin pregnancies medical

A vanishing twin pregnancy occurs when one of a set of twins stops developing early in pregnancy and is naturally absorbed or lost, often after an initial ultrasound showed two embryos. For investors, it matters because the phenomenon can affect demand for fertility services, prenatal testing, and neonatal care, alter clinical trial populations and safety signals, and influence health-care costs and insurance risk assessments—similar to how one failed product in a paired launch changes overall market demand.

EXPAND clinical trial to be presented; data support Fetal Focus™ sgNIPT for inherited conditions

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the EXPAND clinical trial will be featured in an oral plenary presentation at the SMFM meeting, taking place February 8-13, 2026.

EXPAND is a prospective, blinded clinical trial to develop and validate Fetal Focus. Powered by Natera’s proprietary, ultra-sensitive LinkedSNP™ technology, Fetal Focus assesses whether a fetus has inherited disease-causing variants from one or both parents, analyzing 21 genes associated with serious, early-onset medical conditions.

As previously announced, EXPAND validated Fetal Focus’ ability to identify a broad range of clinically relevant inherited conditions with high accuracy. The oral presentation will detail the study’s key results, along with its robust design, including confirmation of all outcomes against genetic truth.

“Being selected for a plenary session at SMFM highlights the high quality of the EXPAND data and its role in advancing prenatal screening,” said Sheetal Parmar, M.S., CGC, senior vice president of medical affairs for women’s health at Natera. “Supporting women’s health is central to Natera’s mission. EXPAND reflects our ongoing commitment to generating high-quality clinical evidence that delivers actionable insights in prenatal care.”

In addition to EXPAND, Natera and its collaborators will deliver a second oral presentation at SMFM highlighting data from VANISH, a prospective clinical trial which validates the unique ability of Panorama™ NIPT to interpret cell-free DNA patterns in vanishing twin pregnancies.

The full list of Natera presentations at SMFM includes:

February 11, 8:45 AM PT | Presentation # 4 (Oral Plenary Presentation)
Presenter: Rajeevi Madankumar, M.D.
Performance of a single gene non-invasive prenatal screening test for recessive conditions

February 11, 10:30 AM PT | Presentation # 145 (Poster)
Presenter: Vivienne Souter, M.D.
Carrier Screening as a Pathway to In-Utero Therapy

February 12, 1:00 PM PT | Presentation # 65 (Oral Presentation)
Presenter: Lorraine Dugoff, M.D.
Development and Validation of a SNP-based cfDNA test for vanishing twin pregnancies: The VANISH Trial

February 12, 3:30 PM PT | Presentation # 1092 (Poster)
Presenter: Jeffrey T. Meltzer, M.D.
Identification of maternal Alzheimer’s disease risk after an atypical finding on SNP-based prenatal cfDNA screening

About Natera

Natera™ is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 350 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260120290888/en/

Investor Relations: Mike Brophy, CFO, Natera, Inc., investor@natera.com

Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com

Source: Natera, Inc.